newsfilter
← Earnings
Earnings Releases·

Pyxis Oncology — Third Quarter 2026 Earnings Summary

  • Net loss narrowed to $20.0 million ($0.24 per share) from $22.0 million ($0.35 per share) in Q3 2025, driven by a reduction in total operating expenses to $20.5 million from $23.5 million, while cash and investments totaled $57.0 million.
  • The company closed a public offering on October 1, 2026, generating $110.0 million in net proceeds, with potential additional proceeds of $172.6 million via warrant exercises, extending cash runway into the first half of 2028.
  • Clinical progress includes confirmed Phase 1 monotherapy data showing a 36% objective response rate in 2L+ R/M HNSCC, with FDA feedback on Phase 3 Headliner trial dose selection expected in Q1 2027 and trial initiation planned for mid-2027.
  • Leadership changes include the appointment of Tom Civik as CEO and Chairman in September 2026 and the transition of John Flavin to Lead Independent Director, alongside a corporate strategy update scheduled for December 2026.
Company
PYXIS ONCOLOGY INC
Sector
Healthcare
Industry
Biotechnology